Objectives: The paper explores the attempt by an American biotechnology company, Myriad Genetics, to use its patent rights over the BRCA genes to transfer its technology of genetic testing for breast and ovarian cancer to Britain. It also investigates the responses of British scientists, health care professionals and patient advocates to this attempted technology transfer. Methods: This paper is based on approximately 100 in-depth interviews, document analysis and ethnographic observation conducted in the United States and Britain from 1998 to 2001. Results: The BRCA gene patents inspired political resistance and mobilized opposition to the patenting of genes in general. They also provided an opportunity for the British to assert their national identity as they argued that a British BRCA testing service needed to be available within the context of the National Health Service to all citizens equally. Conclusions: Patents are not only legal documents and technical descriptions, but political tools as well. As they are increasingly deemed vital to economic globalization, patents have become mobilizing tools for anti-globalization activists and non-governmental organizations from less developed countries, and for asserting local and national identities.

1.
Davies K, White M: Breakthrough: The Race to Find the Breast Cancer Gene. New York, Wiley, 1995.
2.
Parthasarathy S: Architectures of genetic medicine: comparing genetic testing for breast cancer in the USA and UK. Soc Stud Sci 2005;35:5–40.
3.
Myriad Genetics, Inc: Myriad Genetics hosting conference of European experts on breast cancer genetic testing. Salt Lake City, press release, 1998.
4.
British Society for Human Genetics: BSHG statement on patenting and clinical genetics. 1998. http://www.bham.ac.uk/BSHG/patent2.htm.
5.
Meek J: Money and the meaning of life; business and science in race to crack the genetic code. The Guardian, January 17, 2000.
6.
Ross E: Scientists object to gene patent. Associated Press, January 18, 2000.
7.
Mulkay MJ: Norms and ideology in science. Soc Sci Inf 1976;15:637–656.
8.
Connor S: Concern over cancer gene patent. The Independent, September 15, 1994.
9.
Dalpé R, Bouchard L, Houle A, Bédard L: Watching the race to find the breast cancer genes. Sci Technol Human Values 2003;28:187–216.
10.
Dobson R: Women fight patent on cancer test. The Sunday Times, April 20, 1997.
11.
Merz JF: Are there limits on what may be patented? In Magnus D, Caplan A, McGee G (eds): Who Owns Life? New York, Prometheus, 2002.
12.
British Society for Human Genetics: Patenting of human gene sequences and the EU Draft Directive. 1997.
13.
Lewin T: Move to patent gene is called obstacle to research. The New York Times, May 21, 1996, A14.
14.
National Breast Cancer Coalition: Gene patenting: yes or no? Call to action! The Quarterly Newsletter of the National Breast Cancer Coalition and the National Breast Cancer Coalition Fund, Fall/Winter 1997.
15.
Kenney M: Biotechnology and the Creation of a New Economic Space. Private Science: Biotechnology and the Rise of the Molecular Sciences. Philadelphia, University of Pennsylvania Press, 1998.
16.
Clinical Molecular Genetics Society: Gene patents and clinical molecular genetic testing in the UK. Report 1999.
17.
Myriad Genetics: Myriad Genetics launches genetic testing in the United Kingdom and Ireland. Press release, March 2000.
18.
Rosgen Ltd: UK company announces licensing agreement for breast cancer genetic testing. Press release, March 2000.
19.
Southwest Thames Regional Genetics Service: Stop press: Myriad Genetics attempt to monopolize breast cancer testing. 2000. http://www.genetics-swt.org/oldnews.htm.
20.
Matthijs G, Halley D: European-wide opposition against the breast cancer gene patents. Eur J Hum Genet 2002;10:783–785.
21.
Institut Curie: Breast and ovarian cancer susceptibility gene BRCA: another victory for opponents of patents held by Myriad Genetics: European Patent Office rejects the essential points of BRCA1 gene patents. Press release, January 2005.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.